Freeman, K., Connock, M., Auguste, P., Taylor-Phillips, S., Mistry, H., Shyangdan, D., . . . Clarke, A. (2016). Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: Systematic reviews and economic modelling. Health Technol Assess.
Citação norma ChicagoFreeman, Karoline, et al. "Clinical Effectiveness and Cost-effectiveness of Use of Therapeutic Monitoring of Tumour Necrosis Factor Alpha (TNF-α) Inhibitors [LISA-TRACKER® Enzyme-linked Immunosorbent Assay (ELISA) Kits, TNF-α-Blocker ELISA Kits and Promonitor® ELISA Kits] Versus Standard Care in Patients With Crohn's Disease: Systematic Reviews and Economic Modelling." Health Technol Assess 2016.
Deismireacht MLAFreeman, Karoline, et al. "Clinical Effectiveness and Cost-effectiveness of Use of Therapeutic Monitoring of Tumour Necrosis Factor Alpha (TNF-α) Inhibitors [LISA-TRACKER® Enzyme-linked Immunosorbent Assay (ELISA) Kits, TNF-α-Blocker ELISA Kits and Promonitor® ELISA Kits] Versus Standard Care in Patients With Crohn's Disease: Systematic Reviews and Economic Modelling." Health Technol Assess 2016.